Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigral's revenue for the
three
months ended in Jun. 2026 was ₹7,054 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was ₹26,260 Mil.
Epigral's Revenue per Share for the
three
months ended in Jun. 2026 was ₹162.59.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was ₹607.79.
Warning Sign:
Epigral Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Epigral was 3.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 26.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 9 years, Epigral's highest 3-Year average Revenue per Share Growth Rate was 52.60% per year. The lowest was -0.50% per year. And the median was 23.30% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Epigral Revenue Related Terms
Epigral Revenue Historical Data
* Premium members only.
The historical data trend for Epigral's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Epigral's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigral Revenue vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Epigral's Revenue distribution charts can be found below:
* The bar in red indicates where Epigral's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹26,260 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Epigral (NSE:EPIGRAL) has a Revenue of ₹26,260 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Epigral and its competitors.
Is Epigral's Revenue too high?
Epigral's current Revenue is ₹26,260 Mil. Overall, Epigral has a GF Score™ of 89/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Epigral's Revenue compare to DOW?
Epigral's Revenue of ₹26,260 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Chemicals company?
A good Revenue depends on the Chemicals industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Epigral and its competitors. Epigral's current Revenue is ₹26,260 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigral stock overvalued right now?
Based on GuruFocus' analysis, Epigral (NSE:EPIGRAL) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹1,711.85, compared to a current price of ₹1,126.00 — trading 34.2% below its estimated fair value. The current Revenue is ₹26,260 Mil. Epigral's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Epigral (NSE:EPIGRAL), the current Revenue is ₹26,260 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigral (NSE:EPIGRAL) Overvalued in 2026?
Based on GuruFocus' analysis, Epigral stock appears to be undervalued.
The current stock price of ₹1,126.00 is trading 34.2% below its estimated GF Value™ of ₹1,711.85.
GuruFocus considers Epigral to be Significantly Undervalued.
Key valuation signals for NSE:EPIGRAL:
Revenue: ₹26,260 Mil
GF Value™: ₹1,711.85 vs. price of ₹1,126.00 (34.2% below fair value)
No single metric tells the full story. See the NSE:EPIGRAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigral Ltd is a producer of Chlor-Alkali and its Derivatives and specialty chemicals with backward and forward integration facilities. It manufactures Caustic Soda, Caustic Potash, CPVC Resin, Epichlorohydrin, Chlorine, Hydrogen, Chloromethanes, and Hydrogen Peroxide. The company is focused on servicing domestic as well as international markets.
89GF Score
Get the complete analysis for NSE:EPIGRAL
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:EPIGRAL has been successfully added to your 
